Sobi agrees to pay up to $300M to reduce royalty payments to Apellis on Empaveli

1st July 2025 Uncategorised 0

Apellis and Sobi have amended their partnership agreement for paroxysmal nocturnal hemoglobinuria treatment Empaveli, or Aspaveli as it is known in Europe. With the new deal, Stockholm-based Sobi agreed to pay $275 million upfront and up to $25 million in potential milestones to reduce its ex-U.S. royalty obligations.

More: Sobi agrees to pay up to 0M to reduce royalty payments to Apellis on Empaveli
Source: fierce